• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney.

作者信息

Grodin Justin L, Tang W H Wilson

机构信息

University of Texas Southwestern Medical Center, Dallas, TX (J.L.G.).

Cleveland Clinic, Cleveland, OH (W.H.W.T.).

出版信息

Circulation. 2020 Sep 15;142(11):1055-1058. doi: 10.1161/CIRCULATIONAHA.120.048057. Epub 2020 Sep 14.

DOI:10.1161/CIRCULATIONAHA.120.048057
PMID:32924569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7495489/
Abstract
摘要

相似文献

1
Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure: Priming the Natriuretic and Metabolic Reserve of the Kidney.用于治疗心力衰竭的钠-葡萄糖协同转运蛋白2抑制剂和襻利尿剂：激发肾脏的利钠和代谢储备
Circulation. 2020 Sep 15;142(11):1055-1058. doi: 10.1161/CIRCULATIONAHA.120.048057. Epub 2020 Sep 14.
2
Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodium-glucose cotransporter-2 inhibitors?
J Cardiovasc Med (Hagerstown). 2020 Apr;21(4):343. doi: 10.2459/JCM.0000000000000938.
3
Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin?心力衰竭中利尿剂抵抗：恩格列净有作用吗？
Curr Vasc Pharmacol. 2019;17(4):421-424. doi: 10.2174/1570161116666180831124717.
4
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂对合并2型糖尿病的心力衰竭患者短期利钠作用的机制及预测
Heart Vessels. 2020 Sep;35(9):1218-1226. doi: 10.1007/s00380-020-01597-x. Epub 2020 Apr 8.
5
Importance of sodium-glucose cotransporter 2 inhibitor use in diabetic patients with acute heart failure.钠-葡萄糖协同转运蛋白2抑制剂在急性心力衰竭糖尿病患者中的应用重要性。
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719894509. doi: 10.1177/1753944719894509.
6
Response to letter: 'Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for SGLT-2 inhibitors?'.
J Cardiovasc Med (Hagerstown). 2020 Apr;21(4):344. doi: 10.2459/JCM.0000000000000947.
7
Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂联合袢利尿剂对慢性心力衰竭糖尿病患者的肾脏和心血管影响（RECEDE-CHF）：一项随机对照双盲交叉试验方案
BMJ Open. 2017 Oct 16;7(10):e018097. doi: 10.1136/bmjopen-2017-018097.
8
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics.恩格列净对心肺适应性的影响及袢利尿剂的显著相互作用。
Diabetes Obes Metab. 2018 Aug;20(8):2014-2018. doi: 10.1111/dom.13309. Epub 2018 Apr 23.
9
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.在 2 型糖尿病合并慢性心力衰竭患者中 SGLT2 抑制剂联合袢利尿剂的肾脏和心血管影响：RECEDE-CHF 试验。
Circulation. 2020 Nov 3;142(18):1713-1724. doi: 10.1161/CIRCULATIONAHA.120.048739. Epub 2020 Aug 29.
10
Risk of volume depletion events with concomitant use of sodium glucose co-transporter 2 inhibitors and loop diuretics: A self-controlled case series study.钠-葡萄糖协同转运蛋白 2 抑制剂与袢利尿剂联用致血容量不足事件风险：一项自身对照病例系列研究。
Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1102-1109. doi: 10.1002/pds.5496. Epub 2022 Jul 1.

引用本文的文献

1
Diuretics: a review of the pharmacology and effects on glucose homeostasis.利尿剂：药理学及其对葡萄糖稳态影响的综述
Front Pharmacol. 2025 Mar 28;16:1513125. doi: 10.3389/fphar.2025.1513125. eCollection 2025.
2
Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study.钠-葡萄糖协同转运蛋白2抑制剂对心力衰竭患者利尿剂剂量影响的真实世界证据：一项回顾性队列研究。
Front Pharmacol. 2024 Apr 2;15:1366439. doi: 10.3389/fphar.2024.1366439. eCollection 2024.
3
The roles of sodium and volume overload on hypertension in chronic kidney disease.钠和容量超负荷在慢性肾脏病高血压中的作用。
Kidney Res Clin Pract. 2021 Dec;40(4):542-554. doi: 10.23876/j.krcp.21.800. Epub 2021 Nov 17.
4
Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population.钠-葡萄糖协同转运蛋白2抑制剂的使用与射血分数保留的心力衰竭合并2型糖尿病患者心力衰竭住院风险降低相关：一项针对不同城市人群的真实世界研究
Drugs Real World Outcomes. 2022 Mar;9(1):53-62. doi: 10.1007/s40801-021-00277-0. Epub 2021 Sep 3.

本文引用的文献

1
Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis.达格列净抑制铁调素并增加红细胞生成。
J Clin Endocrinol Metab. 2020 Apr 1;105(4). doi: 10.1210/clinem/dgaa057.
2
Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.钠-葡萄糖共转运蛋白 2 抑制剂的心脏保护作用：从肾脏近端小管的角度来看。
Am J Physiol Cell Physiol. 2020 Feb 1;318(2):C328-C336. doi: 10.1152/ajpcell.00275.2019. Epub 2019 Nov 13.
3
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease.恩格列净对2型糖尿病合并冠状动脉疾病患者促红细胞生成素水平、铁储备及红细胞形态的影响
Circulation. 2020 Feb 25;141(8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235. Epub 2019 Nov 11.
4
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
5
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.SGLT2 抑制剂的肾脏和心血管保护机制评估：基于模型的临床数据分析。
Am J Physiol Renal Physiol. 2018 Nov 1;315(5):F1295-F1306. doi: 10.1152/ajprenal.00202.2018. Epub 2018 Jul 18.
6
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.钠-葡萄糖协同转运蛋白 2 抑制剂达格列净与袢利尿剂布美他尼在健康人体中的相互作用。
J Am Heart Assoc. 2018 Feb 10;7(4):e007046. doi: 10.1161/JAHA.117.007046.
7
Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys.钠-葡萄糖协同转运蛋白2抑制剂治疗期间血细胞比容升高表明糖尿病肾病肾小管间质功能恢复
J Clin Med Res. 2016 Dec;8(12):844-847. doi: 10.14740/jocmr2760w. Epub 2016 Oct 26.
8
Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF).血清氯化物稳态在急性心力衰竭中的意义（来自ROSE-AHF研究）
Am J Cardiol. 2017 Jan 1;119(1):78-83. doi: 10.1016/j.amjcard.2016.09.014. Epub 2016 Sep 30.
9
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
10
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂通过增加糖尿改变肾小管尿酸转运活性来降低血清尿酸水平。
Biopharm Drug Dispos. 2014 Oct;35(7):391-404. doi: 10.1002/bdd.1909. Epub 2014 Aug 6.